Finally, TP53 mutation of predicted target genes (PDCD6, GNG5, PHF6, MAL2, SLC25A15 and PTDSS1) has guiding significance for drug selection in BLCA. This evidence concerns the gene PTDSS1 and bladder transitional cell carcinoma.